Live Feeds
● LIVE Updated 11d ago · 15 sources tracked

Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America

Eli Lilly CEO David Ricks asserts that GLP-1 drugs will be more transformative than artificial intelligence. The company currently controls 60% of the GLP-1 market following a 125% revenue surge for Mounjaro. New oral GLP-1 medications are also in development to move beyond injections.

RSS Source map (15)

What changed

CEO David Ricks compared the impact of GLP-1s to AI and updated market share data was released.

Live updates

  1. Eli Lilly CEO Claims GLP-1s More Transformative Than AI

    Eli Lilly CEO David Ricks asserts that GLP-1 drugs will be more transformative than artificial intelligence. The company currently controls 60% of the GLP-1 market following a 125% revenue surge for Mounjaro. New oral GLP-1 medications are also in development to move beyond injections.

    What's confirmed:

    • Eli Lilly CEO David Ricks stated on June 5 that GLP-1 drugs will be a more transformative technology than artificial intelligence.
    • David Ricks described artificial intelligence as overhyped and GLP-1s as underhyped.
    • Eli Lilly controls 60% of the GLP-1 market.
    • Mounjaro revenue increased by 125% according to Lilly's Q1 2026 earnings report.

    Still unconfirmed:

    • A new oral GLP-1 drug delivers up to 12% weight loss in 36 weeks.
    • A new GLP-1 pill leads to 16% weight loss in a year and can be taken anytime.
    • Orforglipron is being used for obesity management.
    • Betul Hatipoglu is researching a GLP-1 pill for weight loss.
    confidence 90%